Cancidas® (caspofungin acetate) – First-time generic
August 1, 2017 – Fresenius announced the launch of an AP-rated generic equivalent of Merck’s Cancidas (caspofungin acetate) injection, indicated in adults and pediatric patients (3 months of age and older) for empirical therapy for presumed fungal infections in febrile, neutropenic patients; treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections; treatment of esophageal candidiasis; and treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Top